Retrospective evaluation of the dose received by the ovary after radioactive iodine therapy for thyroid cancer.
In an earlier study, we evaluated the frequency of clinical manifestations of ovarian insufficiency after radioiodine therapy for thyroid cancer. We were thus led to consider the dose received by the ovary (DRO) during these treatments. In the literature, this dose is expressed as a function of the activity administered. However, in our study, the disorders were not correlated with the activity administered. Faced with this discrepancy, we have attempted to establish a dosimetric model using the parameters available for each patient. The results obtained show that besides the activity administered, which plays a role, morphological and kinetic factors specific to each individual have an importance that cannot be ignored when addressing this problem.
Izembart
M
M
Service Central de Radioisotopes, Hôpital Necker Enfants Malades, Paris, France.
Chavaudra
J
J
Aubert
B
B
Vallée
G
G
D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010053:Ovary / Q000378:metabolism*; D010297:Paris / Q000453:epidemiology; D011829:Radiation Dosage; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000453:epidemiology / Q000532:radiotherapy*
D007457:Iodine Radioisotopes